Effects of lumacaftor-ivacaftor therapy on cystic fibrosis transmembrane conductance regulator function in F508del homozygous patients with cystic fibrosis aged 2-11 years.

Front Pharmacol · 2023 · PMC10266342 · PMID 37324488

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

an increasing trendno p-value reported

Regarding weight gain in patients treated with LUM/IVA, there was an increasing trend in BMI z-score, but this was not significant ( p -value 0.25).

also in 63,971 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.